End­points News poll: Let's get your opin­ion on that con­tro­ver­sial ad­u­canum­ab ap­proval

If there’s one thing that’s ab­solute­ly clear in the dust­up over the ad­u­canum­ab ap­proval, it’s that most every­one who can reg­is­ter an opin­ion has fired off some­thing, some­where. Now it’s your turn as we size up the bio­phar­ma in­dus­try’s mood on this im­por­tant is­sue.

We’ve as­sem­bled a set of 4 ques­tions for this in­dus­try sur­vey gaug­ing your opin­ion on the FDA’s ac­tions in­volv­ing one of the most con­tro­ver­sial de­ci­sions the agency has ever hand­ed down. It should on­ly take a few min­utes to com­plete.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER